# Jasper Therapeutics (JSPR) — News

JSPR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/jspr/news

## Recent headlines

- [Jasper Therapeutics - First FSGS patient in phase 2 study expected to be dosed in Q1 2027](https://www.ainvest.com/news/jasper-therapeutics-fsgs-patient-phase-2-study-expected-dosed-q1-2027-2610) — AInvest Wire, Oct 15, 2026
  Jasper Therapeutics, Inc. (Nasdaq: JSPR) has announced that the first patient in the focal segmental glomerulosclerosis (FSGS) cohort of its Phase 2 basket study of vensobafusp alfa (KP104) is expected to be dosed in Q1 2027 . This follows the completion of enrollment for the IgA nephropathy (IgAN)…
- [Jasper Therapeutics - Initial interim data from IGAN study expected by year-end 2026](https://www.ainvest.com/news/jasper-therapeutics-initial-interim-data-igan-study-expected-year-2026-2610) — AInvest Wire, Oct 15, 2026
- [Jasper Therapeutics, Inc.: William Blair resumes coverage with outperform rating](https://www.ainvest.com/news/jasper-therapeutics-william-blair-resumes-coverage-outperform-rating-2610) — AInvest Wire, Oct 14, 2026
- [RPT-Jasper Therapeutics announces commencement of an offer to purchase outstanding warrants](https://www.ainvest.com/news/rpt-jasper-therapeutics-announces-commencement-offer-purchase-outstanding-warrants-2610) — AInvest Wire, Oct 7, 2026
  Jasper Therapeutics has announced the commencement of an offer to purchase its outstanding warrants, according to a recent filing. The company has initiated the tender offer as part of its ongoing efforts to manage its capital structure and enhance shareholder value. Specific terms of the offer,…
- [Jasper Therapeutics - Offer purchase price is $0.32 in cash per warrant](https://www.ainvest.com/news/jasper-therapeutics-offer-purchase-price-0-32-cash-warrant-2610) — AInvest Wire, Oct 7, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).